These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 30231360)

  • 41. Peri-operative therapy for operable gastroesophageal adenocarcinoma: past, present and future.
    Aggelis V; Cunningham D; Lordick F; Smyth EC
    Ann Oncol; 2018 Jun; 29(6):1377-1385. PubMed ID: 29771279
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Impact of postoperative TNM stages after neoadjuvant therapy on prognosis of adenocarcinoma of the gastro-oesophageal junction tumours.
    Thomaschewski M; Hummel R; Petrova E; Knief J; Wellner UF; Keck T; Bausch D
    World J Gastroenterol; 2018 Apr; 24(13):1429-1439. PubMed ID: 29632424
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Third international conference of the European Union Network of Excellence on gastric and esophagogastric junction cancer, Cologne, Germany, June 2012.
    Moenig SP; Meyer HJ; Allum WH; De Manzoni G; Garofalo A; Baltin CT; Fetzner UK; Hoelscher AH
    Gastric Cancer; 2015 Jan; 18(1):193-9. PubMed ID: 24522716
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Management of early-stage gastro-esophageal cancers: expert perspectives from the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty.
    Roy AC; Shapiro J; Burge M; Karapetis CS; Pavlakis N; Segelov E; Chau I; Lordick F; Chen LT; Barbour A; Tebbutt N; Price T
    Expert Rev Anticancer Ther; 2020 Apr; 20(4):305-324. PubMed ID: 32202178
    [No Abstract]   [Full Text] [Related]  

  • 45. The RENAISSANCE (AIO-FLOT5) trial: effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction - a phase III trial of the German AIO/CAO-V/CAOGI.
    Al-Batran SE; Goetze TO; Mueller DW; Vogel A; Winkler M; Lorenzen S; Novotny A; Pauligk C; Homann N; Jungbluth T; Reissfelder C; Caca K; Retter S; Horndasch E; Gumpp J; Bolling C; Fuchs KH; Blau W; Padberg W; Pohl M; Wunsch A; Michl P; Mannes F; Schwarzbach M; Schmalenberg H; Hohaus M; Scholz C; Benckert C; Knorrenschild JR; Kanngießer V; Zander T; Alakus H; Hofheinz RD; Roedel C; Shah MA; Sasako M; Lorenz D; Izbicki J; Bechstein WO; Lang H; Moenig SP
    BMC Cancer; 2017 Dec; 17(1):893. PubMed ID: 29282088
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The role of adjuvant platinum-based chemotherapy in esophagogastric cancer patients who received neoadjuvant chemotherapy prior to definitive surgery.
    Saunders JH; Bowman CR; Reece-Smith AM; Pang V; Dorrington MS; Mumtaz E; Soomro I; Kaye P; Madhusudan S; Parsons SL
    J Surg Oncol; 2017 Jun; 115(7):821-829. PubMed ID: 28257148
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Gastroesophageal Junction Adenocarcinoma: Is There an Optimal Management?
    Lin D; Khan U; Goetze TO; Reizine N; Goodman KA; Shah MA; Catenacci DV; Al-Batran SE; Posey JA
    Am Soc Clin Oncol Educ Book; 2019 Jan; 39():e88-e95. PubMed ID: 31099690
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Radiotherapy for tumors of the stomach and gastroesophageal junction--a review of its role in multimodal therapy.
    Buergy D; Lohr F; Baack T; Siebenlist K; Haneder S; Michaely H; Wenz F; Boda-Heggemann J
    Radiat Oncol; 2012 Nov; 7():192. PubMed ID: 23157945
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Multimodal therapy of tumors of the upper gastrointestinal tract].
    Fink U; Stein HJ; Siewert JR
    Chirurg; 1998 Apr; 69(4):349-59. PubMed ID: 9612616
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Correlation of pathological complete response with survival after neoadjuvant chemotherapy in gastric or gastroesophageal junction cancer treated with radical surgery: A meta-analysis.
    Li Z; Shan F; Wang Y; Zhang Y; Zhang L; Li S; Jia Y; Xue K; Miao R; Li Z; Ji J
    PLoS One; 2018; 13(1):e0189294. PubMed ID: 29370182
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Multi-modality therapy for cancer of the esophagus and GE junction.
    Tejani MA; Burtness BA
    Curr Treat Options Oncol; 2012 Sep; 13(3):390-402. PubMed ID: 22592595
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The impact of preoperative radiochemotherapy on survival in advanced esophagogastric junction signet ring cell adenocarcinoma.
    Bekkar S; Gronnier C; Messager M; Robb WB; Piessen G; Mariette C;
    Ann Thorac Surg; 2014 Jan; 97(1):303-10. PubMed ID: 24200394
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Short-term efficacy and safety of the synchronous neoadjuvant chemoradiotherapy with paclitaxel plus carboplatin in stage III adenocarcinoma of esophagogastric junction].
    Ji Y; Peng T; Wang G; Zhang Y; Cao M; Gao Q; Li S
    Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Sep; 21(9):1019-1024. PubMed ID: 30269322
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Refining esophageal cancer staging after neoadjuvant therapy: importance of treatment response.
    Barbour AP; Jones M; Gonen M; Gotley DC; Thomas J; Thomson DB; Burmeister B; Smithers BM
    Ann Surg Oncol; 2008 Oct; 15(10):2894-902. PubMed ID: 18663531
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A phase II study of neoadjuvant docetaxel, oxaliplatin, and S-1 (DOS) chemotherapy followed by surgery and adjuvant S-1 chemotherapy in potentially resectable gastric or gastroesophageal junction adenocarcinoma.
    Park I; Ryu MH; Choi YH; Kang HJ; Yook JH; Park YS; Kim HJ; Jung HY; Lee GH; Kim KC; Kim BS; Kang YK
    Cancer Chemother Pharmacol; 2013 Oct; 72(4):815-23. PubMed ID: 23921575
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Staging of adenocarcinoma of the gastroesophageal junction.
    Parry K; Haverkamp L; Bruijnen RC; Siersema PD; Offerhaus GJ; Ruurda JP; van Hillegersberg R
    Eur J Surg Oncol; 2016 Mar; 42(3):400-6. PubMed ID: 26777127
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Esophageal and esophagogastric junction cancers, version 1.2015.
    Ajani JA; D'Amico TA; Almhanna K; Bentrem DJ; Besh S; Chao J; Das P; Denlinger C; Fanta P; Fuchs CS; Gerdes H; Glasgow RE; Hayman JA; Hochwald S; Hofstetter WL; Ilson DH; Jaroszewski D; Jasperson K; Keswani RN; Kleinberg LR; Korn WM; Leong S; Lockhart AC; Mulcahy MF; Orringer MB; Posey JA; Poultsides GA; Sasson AR; Scott WJ; Strong VE; Varghese TK; Washington MK; Willett CG; Wright CD; Zelman D; McMillian N; Sundar H;
    J Natl Compr Canc Netw; 2015 Feb; 13(2):194-227. PubMed ID: 25691612
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Updated evidence on adjuvant treatments for gastric cancer.
    Kanda M; Kodera Y; Sakamoto J
    Expert Rev Gastroenterol Hepatol; 2015; 9(12):1549-60. PubMed ID: 26414453
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Adjuvant (postoperative) therapy for esophageal cancer.
    Ku GY; Ilson DH
    Thorac Surg Clin; 2013 Nov; 23(4):525-33. PubMed ID: 24199702
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The rationale and evidence for radiotherapy in the management of gastroesophageal junction tumors.
    Haustermans K
    Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714484
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.